Dendreon Presentation at Cancer Immunotherapy Conference

This corporate presentation was recorded during “Cancer Immunotherapy: A Long Awaited Reality”, a conference hosted by BioBusiness.TV and MD Becker Partners on October 21st, 2010, at the New York Academy of Medicine.

Featuring :

• David L. Urdal, PhD, Chief Scientific Officer, Dendreon

Forward Looking Statement :

This presentation includes forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward looking statements by their nature involve risks, uncertainties and assumptions inherent in discussing future events and trends, including many concerning the commercialization of PROVENGE (sipuleucel-T). Information concerning risk factors that may affect such statements can be obtained in the Company’s SEC filings.

Related Videos:

1. ImmunoCellular Therapeutics Presentation at Cancer Immunotherapy Conference
2. Biovest International Presentation at Cancer Immunotherapy Conference
3. Provectus Presentation at Cancer Immunotherapy Conference
4. Celldex Presentation at Cancer Immunotherapy Conference
5. Northwest Biotherapeutics Presentation at Cancer Immunotherapy Conference
6. BioSante Presentation at Cancer Immunotherapy Conference
7. Vaccinogen Presentation at Cancer Immunotherapy Conference
8. Inovio Presentation at Cancer Immunotherapy Conference
9. Bavarian Presentation at Cancer Immunotherapy Conference
10. Argos Therapeutics Presentation at Cancer Immunotherapy Conference